Assignee
ROUSSY INST GUSTAVE
FR·48 granted patents·31 pending applications·488 citations·filing 1995–2025
Top patents by PatentIndex Score
79 records- 0193US6939862B2Method for transferring nucleic acid into striated musclesROUSSY INST GUSTAVE·Filed 2001·Granted Sep 6, 2005·114 cites·30 claims
- 0289US10765710B2Combination of oncolytic virus with immune checkpoint modulatorsROUSSY INST GUSTAVE·Filed 2015·Granted Sep 8, 2020·13 cites·14 claims
- 0389US8865653B2Method of treatment for immunogenic treatment resistant cancerROUSSY INST GUSTAVE·Filed 2013·Granted Oct 21, 2014·7 cites·7 claims
- 0489US6723712B2Antiviral agent for use in treatment of cancerROUSSY INST GUSTAVE·Filed 2002·Granted Apr 20, 2004·52 cites·7 claims
- 0589US6410509B1Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatmentROUSSY INST GUSTAVE·Filed 2000·Granted Jun 25, 2002·23 cites·22 claims
- 0689US6143273ATherapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 proteinROUSSY INST GUSTAVE·Filed 1998·Granted Nov 7, 2000·80 cites·5 claims
- 0788US7378249B2Treatment of cancer using TLR3 agonistsROUSSY INST GUSTAVE·Filed 2005·Granted May 27, 2008·11 cites·12 claims
- 0886US7419669B2Peptide epitopes common to antigens of the same multigene familyROUSSY INST GUSTAVE·Filed 2003·Granted Sep 2, 2008·26 cites·3 claims
- 0982US5955300ASoluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodiesROUSSY INST GUSTAVE·Filed 1995·Granted Sep 21, 1999·35 cites·10 claims
- 1081US11684640B2Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-basedROUSSY INST GUSTAVE·Filed 2017·Granted Jun 27, 2023·3 cites·4 claims
- 1181USRE38313ESoluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodiesROUSSY INST GUSTAVE·Filed 1995·Granted Nov 11, 2003·49 cites·15 claims
- 1280US10646521B2Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentROUSSY INST GUSTAVE·Filed 2014·Granted May 12, 2020·3 cites·20 claims
- 1380US2024393340A1Prognosis and predictive biomarkers and biological applications thereofROUSSY INST GUSTAVE·Filed 2024·Application pending·0 cites
- 1478US2022042016A1Identification of a JAK2 Mutation in Polycythemia VeraROUSSY INST GUSTAVE·Filed 2021·Application pending·0 cites
- 1573US11162100B2Identification of a JAK2 mutation in polycythemia veraROUSSY INST GUSTAVE·Filed 2020·Granted Nov 2, 2021·0 cites·8 claims
- 1672US12144839B2Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatmentROUSSY INST GUSTAVE·Filed 2023·Granted Nov 19, 2024·0 cites·4 claims
- 1771US6875844B1Peptide compounds derived from a shifted ORF of the iCE geneROUSSY INST GUSTAVE·Filed 2000·Granted Apr 5, 2005·9 cites·7 claims
- 1870US10563200B2Identification of a JAK2 mutation in Polycythemia VeraROUSSY INST GUSTAVE·Filed 2019·Granted Feb 18, 2020·0 cites·3 claims
- 1969US6514708B2Process for detecting the malignant transformation of human cellsROUSSY INST GUSTAVE·Filed 2001·Granted Feb 4, 2003·2 cites·6 claims
- 2067US6855802B1Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapyROUSSY INST GUSTAVE·Filed 1999·Granted Feb 15, 2005·26 cites·8 claims
- 2167US6849452B1Methods for activating natural killer (NK) cells and means for carrying out said methodsROUSSY INST GUSTAVE·Filed 1999·Granted Feb 1, 2005·31 cites·15 claims
- 2267US2008253998A1Treatment of cancer using tlr3 agonistsROUSSY INST GUSTAVE·Filed 2008·Application pending·0 cites
- 2366US2026061029A1P21 Expressing Monocytes for Cancer Cell TherapyROUSSY INST GUSTAVE·Filed 2025·Application pending·0 cites
- 2462US10364430B2Identification of a JAK2 mutation in polycythemia veraROUSSY INST GUSTAVE·Filed 2014·Granted Jul 30, 2019·0 cites·3 claims
- 2562US7476496B2Method for preparing an extracellular matrix and its use for tumor cell cultureROUSSY INST GUSTAVE·Filed 2003·Granted Jan 13, 2009·1 cites·2 claims
- 2662US2016116480A1Prognosis and predictive biomarkers and biological applications thereofROUSSY INST GUSTAVE·Filed 2014·Application pending·0 cites
- 2761US2024301499A1Method for identifying hard-to-treat osteosarcoma patients at diagnosis and improving their outcome by providing new therapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 2860US11471463B2Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapyROUSSY INST GUSTAVE·Filed 2018·Granted Oct 18, 2022·0 cites·15 claims
- 2960US10969380B2Simultaneous detection of cannibalism and senescence as prognostic marker for cancerROUSSY INST GUSTAVE·Filed 2017·Granted Apr 6, 2021·0 cites·15 claims
- 3060US10125157B2Derivatives of oxazaphosphorines that are pre-activated, use and method of preparationROUSSY INST GUSTAVE·Filed 2016·Granted Nov 13, 2018·0 cites·7 claims
- 3159US11344586B2Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentROUSSY INST GUSTAVE·Filed 2020·Granted May 31, 2022·0 cites·5 claims
- 3257US12514902B2P21 expressing monocytes for cancer cell therapyROUSSY INST GUSTAVE·Filed 2020·Granted Jan 6, 2026·0 cites·16 claims
- 3357US9428530B2Derivatives of oxazaphosphorines that are pre-activated, use and method of preparationROUSSY INST GUSTAVE·Filed 2015·Granted Aug 30, 2016·0 cites·20 claims
- 3456US11517575B2Use of minaprine to reduce tumor growthROUSSY INST GUSTAVE·Filed 2019·Granted Dec 6, 2022·0 cites·7 claims
- 3556US2011229411A1Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatmentROUSSY INST GUSTAVE·Filed 2008·Application pending·0 cites
- 3655US2025264457A1A biomarker and compositions to increase the therapeutic index of neoadjuvant immunotherapy in muscle-invasive urothelial carcinomaROUSSY INST GUSTAVE·Filed 2023·Application pending·0 cites
- 3755US2024398876A1Biological marker of intestinal dysbiosis, useful for predicting the response of a cancer patient to an anti-pdi drugROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 3855US2004192637A1Antiviral agent for use in treatment of cancerROUSSY INST GUSTAVE·Filed 2003·Application pending·0 cites
- 3954US2008317811A1Treatment of Cancer Using Tlr3 AgonistsROUSSY INST GUSTAVE·Filed 2005·Application pending·0 cites
- 4054US2024288449A1Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 4153US2020376052A1Combination of oncolytic virus with immune checkpoint modulatorsROUSSY INST GUSTAVE·Filed 2020·Application pending·0 cites
- 4250US12102672B2Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancerROUSSY INST GUSTAVE·Filed 2018·Granted Oct 1, 2024·0 cites·18 claims
- 4349US2020102353A1Human endogenous retroviral proteinROUSSY INST GUSTAVE·Filed 2019·Application pending·0 cites
- 4448US2025012805A1Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 4548US2006257380A1Use of sirnas for gene silencing in antigen presenting cellsROUSSY INST GUSTAVE·Filed 2002·Application pending·0 cites
- 4648US2024010990A1Methods for the Determination of Invasive Ability of Brain Tumour Cells and for the Diagnosis and Prognosis of Brain TumourROUSSY INST GUSTAVE·Filed 2021·Application pending·0 cites
- 4747US9557333B2Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum levelROUSSY INST GUSTAVE·Filed 2013·Granted Jan 31, 2017·0 cites·5 claims
- 4847US2023302031A1Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress SyndromeROUSSY INST GUSTAVE·Filed 2021·Application pending·0 cites
- 4947US2015232932A1Ankrd26 as a marker for diagnosis of thrombocytopeniasROUSSY INST GUSTAVE·Filed 2013·Application pending·0 cites
- 5047US2025161248A1Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor InhibitorsROUSSY INST GUSTAVE·Filed 2023·Application pending·0 cites
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ROUSSY INST GUSTAVE files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →